A recently completed multi-site double-blind placebo-controlled study found that bupropion
(Wellbutrin XL) increased female orgasmic function in a group of pre-menopausal women with a
diagnosis of hypoactive sexual desire disorder. The purpose of this study is to ascertain
whether bupropion will improve orgasmic function in pre-menopausal women with a primary
complaint of idiopathic orgasmic disorder who do not have hypoactive sexual desire disorder.
This will be a multicenter, placebo-controlled, double blind study of women with a diagnosis
of female orgasm disorder. During a baseline visit, psychiatric, medical, alcohol and drug,
and sexual histories will be obtained. Patients who continue to meet screening
inclusion/exclusion criteria at their baseline visit will be randomly assigned to either
placebo or bupropion XL for 8 weeks. A flexible dosing paradigm will be used. Sexual desire
and activity will be assessed by patient diaries, investigator interview of sexual
functioning every two weeks, and by standardized questionnaire every four weeks. The primary
endpoint will be the increase in orgasm completion as measured by the Changes in Sexual
Functioning Questionnaire-F (CSFQ-F). Secondary endpoints will be changes in sexual arousal,
sexual desire, and sexual pleasure as assessed by the CSFQ-F.